Skip to main content
. 2015 Sep 10;6(33):34245–34257. doi: 10.18632/oncotarget.5196

Figure 1. JAK2 is activated by CXCL12 and mediates B-lymphocyte static adhesion to ICAM-1 and VCAM-1.

Figure 1

A. Cells were treated with buffer (NT) or CXCL12 0.5 μM for indicated times. Mean ± SD. *P < 0.01; **P < 0.001, versus NT. B. Cells were treated for 1 h with vehicle (NT and Control), AG490 100 μM, or P1-TKIP 40 μM, and stimulated with CXCL12 0.5 μM (Agonist) for 120 sec. Mean ± SD. *P < 0.01, versus Control. Static adhesion to ICAM-1 C–D or VCAM-1 E–F. Cells were treated for 1 h with vehicle (Control) or the indicated doses of AG490 (C-E), or with vehicle (Control), P1 40 μM or the indicated doses of P1-TKIP (D–F), and stimulated with buffer (No) or CXCL12 0.5 μM (Agonist). Mean ± SD. *P < 0.001, versus Control (C-E). Mean ± SD. *P < 0.001, versus P1 (D–F). Data are average of n = 10 independent experiments in duplicate using B-cells isolated from 10 different healthy donors.